The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

Novo Nordisk's Victoza (liraglutide) has become the only approved diabetes drug in the GLP-1 agonist class shown to demonstrate a cardiac safety benefit, although it faces competition from a ...

The FDA approved Hikma's first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic ...

Liraglutide, sold under the brand name Victoza for diabetes, is an earlier iteration in the same class as semaglutide, the active ingredient in Ozempic. Both are sold by Danish drug giant Novo ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ... single-patient-use pen that delivers doses of 0.6mg, 1.2mg, or 1.8mg in ...

Diabetes drug Victoza, or liraglutide, is a first generation GLP-1, a class of treatments that has seen overwhelming demand. It has been on the FDA’s shortage list since 2023, and currently ...

Hikma's branded generic will compete with Teva Pharmaceuticals (TEVA.TA), opens new tab authorized generic of Victoza in the United States that was launched earlier this year. Authorized generics ...